Recent News

• 04.10.2025 - BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States
• 03.27.2025 - BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update
• 03.20.2025 - BioRestorative Therapies to Report 2024 Financial Results and Host Conference Call on March 27, 2025
• 02.27.2025 - BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
• 02.27.2025 - BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update
• 02.20.2025 - BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program
• 02.10.2025 - BRTX-100 Front and Center at ORS 2025

Recent Filings

• 03.28.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.27.2025 - EX-99.1 EX-99.1
• 03.27.2025 - 8-K Current report
• 02.28.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.19.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 02.19.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors